Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 31;29(9):2325–2333. doi: 10.1038/s41591-023-02517-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Moderna, Inc. 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 2 — Observed neutralizing antibody titers (GM titer log10) in the pseudovirus assay against Omicron BA.4/BA.5 (a) and ancestral SARS-CoV-2 (D614G) (b) are shown for serum samples collected before the second booster dose of 50-µg of mRNA-1273.222 or 50-µg of mRNA-1273 (prebooster) (day 0), and at 28 days (day 29) after the second booster dose in all participants and those ≥18 to <65 or ≥65 years of age in the per-protocol immunogenicity set without evidence of prebooster SARS-CoV-2 infection. N=Number of participants with nonmissing data at the timepoint; CI=Confidence interval; GMT=geometric mean titer; LLOQ=lower limit of quantification; ULOQ=upper limit of quantification; PPIS=Per-protocol immunogenicity set. Antibody values assessed by pseudovirus neutralizing antibody assay reported as below the LLOQ (18.5 [1.3 in log10 scale] for ancestral SARS-CoV-2 (D614G) and 36.7 [1.6 in log10 scale] for Omicron BA.4/BA.5) are replaced by 0.5 × LLOQ. Values greater than ULOQ (45,118 [4.7 in log10 scale] for ancestral SARS-CoV-2 (D614G) and 13,705 [4.1 in log10 scale] for Omicron BA.4/BA.5) are replaced by the ULOQ if actual values are not available. Includes participants in the per-protocol immunogenicity set without evidence of prebooster SARS-CoV-2 infection (PPIS-negative). 95% CIs were calculated based on the t-distribution of the log-transformed values for GM value, then back-transformed to the original scale for presentation.